MEDLAB has confirmed that its Nanabis medicinal cannabis product is now ready for sale and delivery to Sydney's Royal North Shore Hospital, where it will be part of an "intractable pain" trial commencing next month.
In an update to shareholders yesterday the company said the recent decision by the Council of Australian Health Ministers to progress a single national online application pathway to access unregistered medicinal cannabis products has enabled Medlab to progress its original plans for Nanabis by 12-18 months.
Chairman Michael Hall reiterated that the company was able to sell Nanabis prior to the completion of the RNSH trial results, in line with Special Access Scheme approvals.
"As a result our executive team are already on the road training doctors and pharmacists," he said.
Medlab says that Nanabis, which is a whole cannabis plant extract in a proprietary delivery platform provides a solution to the opioid crisis, and is indicated for advanced cancer pain.
The endpoint of the trial is to demonstrate effective pain management and thus reduce reliance on standard opioid use.
Upon completion of the trial Medlab envisages applying for TGA registration of Nanabis in early 2019.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Apr 18
